Provided by Tiger Trade Technology Pte. Ltd.

Tenax Therapeutics

1.86
-0.0500-2.62%
Pre-market: 1.84-0.0168-0.90%06:10 EDT
Volume:2.40M
Turnover:4.49M
Market Cap:69.61M
PE:-1.27
High:1.91
Open:1.91
Low:1.83
Close:1.91
52wk High:19.40
52wk Low:1.31
Shares:37.42M
Float Shares:17.52M
Volume Ratio:1.57
T/O Rate:13.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4685
EPS(LYR):-1.3412
ROE:-59.80%
ROA:-37.70%
PB:0.61
PE(LYR):-1.39

Loading ...

Tenax Therapeutics - to Amend Level-2 Enrollment Criteria - SEC Filing

THOMSON REUTERS
·
14 hours ago

Tenax Therapeutics - Temporarily Pauses Level-2 Enrollment for Tnx-103 in Ph-Hfpef - SEC Filing

THOMSON REUTERS
·
14 hours ago

Tenax Therapeutics - Requests Type C Meeting with FDA on Levosimendan Development - SEC Filing

THOMSON REUTERS
·
14 hours ago

Tenax Therapeutics: Enrollment May Resume at Each Site as Amended Protocol Goes into Effect

THOMSON REUTERS
·
14 hours ago

Tenax Therapeutics Director Declan Doogan Buys 53,000 Shares Worth $101,760

Reuters
·
Sep 18

Tenax CFO Thomas R. Staab II Buys USD 10,982.63 in Common Shares

Reuters
·
Sep 16

Tenax Therapeutics Releases LEVEL Clinical Trial Results Presentation

Reuters
·
Sep 09

ADAR1 Capital’s Daniel Schneeberger Buys $1.6 Million of Tenax Therapeutics Shares

Reuters
·
Sep 09

ADAR1 Capital Management Reports Tenax Therapeutics Common Share Purchase Worth $1.38 Million

Reuters
·
Sep 03

Tenax Therapeutics CEO to Present at Cantor Global Healthcare Conference

Reuters
·
Sep 01

Piper Sandler Sticks to Their Buy Rating for Tenax Therapeutics (TENX)

TIPRANKS
·
Aug 31

Tenax Therapeutics announces results from Phase 3 LEVEL trial of TNX-103

TIPRANKS
·
Aug 31

Tenax Presents Phase 3 LEVEL Data Showing TNX-103 Boosts 6-Minute Walk Distance in Lower Baseline Subgroup

Reuters
·
Aug 29

Tenax Therapeutics Discloses ADAR1 Capital Management as Beneficial Owner in Form 3 Filing

Reuters
·
Aug 25

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 13

Tenax Therapeutics downgraded to Neutral from Buy at Chardan

TIPRANKS
·
Aug 11

Tenax Therapeutics Price Target Cut to $5.00/Share from $39.00 by Evercore ISI Group

Dow Jones
·
Aug 11

Evercore ISI Downgrades Tenax Therapeutics to In Line From Outperform, Adjusts PT to $5 From $39

MT Newswires Live
·
Aug 11

Tenax Therapeutics Inc : William Blair Cuts to Market Perform Rating

THOMSON REUTERS
·
Aug 11

Tenax Therapeutics price target lowered to $4 from $26 at Leerink

TIPRANKS
·
Aug 11